 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Clinical Specialist, Department of Dermatology, Hospital Juan Canalejo, La Coruña, Spain
Clinical Specialist, Department of Dermatology, Hospital Juan Canalejo
Clinical Specialist, Department of Pathology, Hospital Juan Canalejo
Pharmacist, Department of Pharmacy, Hospital Juan Canalejo
Chief, Department of Dermatology, Hospital Juan Canalejo
Reprints: María M Verea MD, Department of Dermatology, Hospital Juan Canalejo, Xubias de Arriba 84, 15006 La Coruña, Spain, FAX 34 981 205375, der{at}canalejo.org
OBJECTIVE: To report a case of psoriasiform eruption induced by infliximab.
CASE SUMMARY: A 46-year-old woman with enterocutaneous fistula secondary to Crohn's disease developed pruriginous, erythematous, desquamative plaques on her elbows, knees, hands, and buttocks after receiving the second and third doses of intravenous infliximab. Histologic examination showed a lichenoid pattern. No new cutaneous lesions appeared after cessation of infliximab therapy.
DISCUSSION: Several cutaneous reactions secondary to infliximab, a monoclonal antibody against tumor necrosis factor-alfa, have been described. Psoriasiform dermatitis has not been reported as a cutaneous reaction to infliximab, but there have been several previous reports of psoriasiform dermatitis secondary to other drugs. An objective causality assessment revealed that the adverse event was probable.
CONCLUSIONS: This is the first report of a clinico-pathologic dissociated pattern of cutaneous reaction showing a histopathologic picture of lichenoid dermatitis resulting from infliximab treatment.
Key Words: infliximab, psoriasiform eruption
Published Online, December 5, 2003. www.theannals.com, DOI 10.1345/aph.1C477
This article has been cited by other articles:
|
|
 |
|
  J. Seneschal, S. Lepreux, B. Milpied, T. Schaeverbeke, and A. Taieb Psoriasiform Eruptions During Anti TNF-{alpha} Treatment: Psoriasis or Not? Arch Dermatol, December 1, 2007; 143(12): 1593 - 1595. [Full Text] [PDF]
|
|
|
|
|
|
G. C. de Gannes, M. Ghoreishi, J. Pope, A. Russell, D. Bell, S. Adams, K. Shojania, M. Martinka, and J. P. Dutz Psoriasiform Eruptions During Anti TNF-{alpha} Treatment: Psoriasis or Not? Reply Arch Dermatol, December 1, 2007; 143(12): 1595 - 1595. [Full Text] [PDF]
|
|
|
|
|
|
R. Ubriani and A. S. Van Voorhees Onset of Psoriasis During Treatment With TNF-{alpha} Antagonists: A Report of 3 Cases Arch Dermatol, February 1, 2007; 143(2): 270 - 272. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Dale, M. Davis, and D. L. Faustman A role for transcription factor NF-{kappa}B in autoimmunity: possible interactions of genes, sex, and the immune response Advan Physiol Educ, December 1, 2006; 30(4): 152 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Ritchlin and F Tausk A medical conundrum: onset of psoriasis in patients receiving anti-tumour necrosis factor agents. Ann Rheum Dis, December 1, 2006; 65(12): 1541 - 1544. [Full Text] [PDF]
|
|
|
|
|
|
R Peek, R Scott-Jupp, H Strike, J Clinch, and A V Ramanan Psoriasis after treatment of juvenile idiopathic arthritis with etanercept. Ann Rheum Dis, September 1, 2006; 65(9): 1259 - 1259. [Full Text] [PDF]
|
|
|
|
|
|
S Kary, M Worm, H Audring, D Huscher, M Renelt, H Sorensen, E Stander, U Maass, H Lee, W Sterry, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor {alpha} antagonists Ann Rheum Dis, March 1, 2006; 65(3): 405 - 407. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
